These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1761078)

  • 1. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
    Hasselström J; Enquist M; Hermansson J; Dahlqvist R
    Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human pharmacokinetics and metabolism of disopyramide enantiomers.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
    Lima JJ; Boudoulas H; Shields BJ
    Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
    Takahashi H; Tamura A; Ogata H; Masuhara K
    J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
    Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
    J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective pharmacokinetics and pharmacodynamics of disopyramide and its metabolite in rabbits.
    Horikawa M; Yasumuro M; Kanno M; Hanada K; Hashiguchi M; Ogata H
    J Pharm Pharmacol; 2001 Dec; 53(12):1621-8. PubMed ID: 11804392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective pharmacokinetics of disopyramide and interaction with cimetidine.
    Bonde J; Pedersen LE; Nygaard E; Ramsing T; Angelo HR; Kampmann JP
    Br J Clin Pharmacol; 1991 Jun; 31(6):708-10. PubMed ID: 1867965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo interaction of the enantiomers of disopyramide in human subjects.
    Giacomini KM; Nelson WL; Pershe RA; Valdivieso L; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):335-56. PubMed ID: 3772736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
    Aso R; Ohashi K; Katoh T; Ogata H
    Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
    le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
    Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in plasma and urine by use of a chiral cellulose-derivative column.
    Echizen H; Ochiai K; Kato Y; Chiba K; Ishizaki T
    Clin Chem; 1990 Jul; 36(7):1300-4. PubMed ID: 2372941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic activity and unbound concentrations of disopyramide enantiomers in patients.
    Lima JJ; Wenzke SC; Boudoulas H; Schaal SF
    Ther Drug Monit; 1990 Jan; 12(1):23-8. PubMed ID: 2305417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias.
    Le Corre P; Gibassier D; Descaves C; Sado P; Daubert JC; Le Verge R
    J Clin Pharmacol; 1989 Dec; 29(12):1089-96. PubMed ID: 2482304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
    Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
    Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
    Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
    Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.